地舒单抗地舒单抗在临床用于骨质疏松、骨巨细胞瘤、多发性骨髓瘤和实体肿瘤骨转移的治疗。这是目前唯一上市的RANKL抑制剂。它可以与RANK蛋白竞争性结合RANKL蛋白，从而抑制RANKL-RANK-OPG信号通路介导的破骨细胞分化与激活，降低破骨活动， ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

President Trump, in a burst of presidential action unmatched in modern U.S. history, has loosed a flurry of executive orders ...

OSPOMYV™ (denosumab-dssb) injection, for subcutaneous use Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: SELECTED SAFETY INFORMATION CONTRAINDICATIONS These highlights do not ...

Receptor activator of nuclear factor-κB (RANK) is activated by its ligand, RANKL, an essential molecule for osteoclast development: in the absence of RANKL or RANK, osteoclast differentiation ...

This study demonstrated that CAG dose-dependently inhibited osteoclast formation in receptor activator of nuclear factor-κB ligand (RANKL)-stimulated bone marrow macrophage (BMMs). Mechanism studies ...

No writing assistance was utilized in the production of this manuscript. RANKL expression is stimulated in osteoblasts and osteocytes by cytokines and hormones, and plays an important role in ...

尊敬的新老客户：随着寒冬的脚步悄然临近，我们即将迎来中华民族最为盛大的传统节日——春节。为了让大家能够与家人共度一个欢乐、祥和的新春佳节，公司决定对2025年春节假期的安排进行如下通知：本次春节假期将 岁末年初，是我们回望过去、展望未来 ...

Disruption of any step in this cycle might have promising anti-metastasis implications. The interaction of receptor activator of nuclear factor-κB ligand (RANKL) and its receptor RANK is fundamental ...